[go: up one dir, main page]

WO2006062478A1 - Novel treatment of gastrointestinal disorders - Google Patents

Novel treatment of gastrointestinal disorders Download PDF

Info

Publication number
WO2006062478A1
WO2006062478A1 PCT/SE2005/001866 SE2005001866W WO2006062478A1 WO 2006062478 A1 WO2006062478 A1 WO 2006062478A1 SE 2005001866 W SE2005001866 W SE 2005001866W WO 2006062478 A1 WO2006062478 A1 WO 2006062478A1
Authority
WO
WIPO (PCT)
Prior art keywords
butyl
methyl
cyano
azetidin
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2005/001866
Other languages
French (fr)
Inventor
Maria Astin Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of WO2006062478A1 publication Critical patent/WO2006062478A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to the use of dual NK 1 ZNK 2 receptor antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
  • Functional gastrointestinal disorders such as functional dyspepsia
  • the neurokinins also known as the tachykinins, comprise a class of peptide neurotransmitters which are found in the peripheral and central nervous systems.
  • the three principal tachykinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB).
  • SP Substance P
  • NKA Neurokinin A
  • NKB Neurokinin B
  • At least three receptor types are known for the three principal tachykinins.
  • the receptors 5 Based upon their relative selectivities favouring the agonists SP, NKA and NKB, the receptors 5 are classified as neurokinin 1 (NK 1 ), neurokinin 2 (NK 2 ) and neurokinin 3 (NK 3 ) receptors, respectively.
  • Functional gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) and functional dyspepsia are characterized by increased visceral sensations manifested as 30 abdominal discomfort or even pain.
  • the tachykinins which bind to neurokinin (NK) receptors, are present in neurons that transmit signals from the GI tract to the brain.
  • the object of the present invention was to find a new way for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
  • the present invention is directed to the use of dual NKi/NK 2 receptor antagonists for the manufacture of a medicament for the treatment of functional gastrointestinal disorders.
  • One aspect of the present invention is the use of dual NKi/NK 2 receptor antagonists for the manufacture of a medicament for the treatment of functional dyspepsia.
  • Still a further aspect of the present invention is directed to the use of a compound of formula I
  • Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom;
  • Rl is hydrogen, hydroxy, Ci-C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl;
  • R2 and R3 is each and independently selected from hydrogen, Ci-C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, Ci-C 4 alkoxy, halogen and cyano, provided that R2 and R3 may not both be hydrogen;
  • R4 is Ci -C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl;
  • Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1- naphthyl; 5,6,7,8-tetrahydro-l-naphthyl; quinolinyl; 2,3-dihydro-l,4-benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8-tetrahydroisoquinolinyl;
  • the functional gastrointestinal disorder is functional dyspepsia.
  • the heterocyclic ring Het is connected to the rest of the molecule at one of the nitrogen atoms of the ring.
  • heterocyclic rings are optionally substituted l,4-dioxa-8-azaspiro[4.5]decano; optionally substituted piperidino; optionally substituted azepano; optionally substituted pyrrolidino; optionally substituted morpholino; optionally substituted oxazepano; optionally substituted thiomorpholino; optionally substituted thiazepano; and optionally substituted piperazino.
  • Het is piperidino optionally substituted with hydroxy, hydroxyalkyl, oxo, methylthio, methylsulfinyl, methylsulfonyl, cyano, 1,3- dioxolan-2-yl, C 1 -C 4 alkoxy, amino optionally mono or disubstituted with C 1 -C 4 alkyl, C 3 - C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, acylamino optionally N-substituted with Ci- C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, (Ci-C 4 alkylsulfonyl)amino optionally N-substituted by Ci-C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -
  • Ar may optionally be substituted at one or more of its carbon atoms by one or more groups independently selected from cyano, halogen, C 1 -C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, nitro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, Ci-C 4 alkylsulfinyl, C]-C 4 alkylsulfonyl, Ci-C 4 alkylthio, trifluoromethylsulfonyloxy, Ci- C 4 alkyl sulfonyl or Ci-C 4 acyl.
  • groups independently selected from cyano, halogen, C 1 -C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 al
  • Ar is phenyl substituted by one or more groups independently selected from cyano, halogen, Ci-C 4 allcyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, Ci-C 4 alkoxy, nitro, trifluoromethoxy, difluoromethoxy, Ci-C 4 alkylsulfinyl, Ci-C 4 alkylsulfonyl, Ci-C 4 alkylthio, trifluoromethylsulfonyloxy, Cj-C 4 alkyl sulfonyl or Ci-C 4 acyl.
  • Ar is phenyl substituted in its 3- and 5- position by groups independently selected from halogen, Ci-C 4 alkyl, Ci-C 4 alkoxy, cyano and nitro.
  • Ar may additionally also be substituted in its 2- and/or 4-position by a group independently selected from halogen, Ci-C 4 alkyl and Ci-C 4 alkoxy.
  • Rl is hydrogen
  • R2 and R3 are both chloro or one is fluoro and the other is hydrogen. In a further embodiment of the invention, R2 and R3 are both chloro and attached in the three and four position of the phenyl ring or R2 is fluoro attached in the four position and R3 is hydrogen.
  • R4 is methyl.
  • the compound of formula I is the S- enantiomer or the racemate. In a further embodiment of the invention, the compound of formula I is the S-enantiomer.
  • the compound of formula I is the R- enantiomer or the racemate. In a further embodiment of the invention, the compound of formula I is the R-enantiomer.
  • a further aspect of the invention relates to compounds of formula I, wherein Het is tbiomorpholino, morpholino or oxidothiomorpholino; Rl is H;
  • R2 is fluoro and R3 is hydrogen, fluoro being preferably in para position;
  • Ar is 3-cyano-5,6,7,8-tetrahydro-l-naphthyl; and R4 is as defined above.
  • a further aspect of the invention is the use of any of the following compounds for the treatment of functional gastrointestinal disorders, such as functional dyspepsia:
  • the compounds useful in accordance with the present invention are capable of forming salts with various inorganic and organic acids and such salts are also within the scope of this invention.
  • acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, cyclohexyl sulfamate, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2- hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, palmoate, persulfate, phenylacetate, phosphate, picrate, pivalate
  • Non-pharmaceutically-acceptable salts may be prepared from the corresponding acid in conventional manner.
  • Non-pharmaceutically-acceptable salts may be useful as intermediates and as such are another aspect of the present invention.
  • Acid addition salts may also be in the form of polymeric salts such as polymeric sulfonates.
  • the salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.
  • Compounds of formula I have one or more chiral centres, and it is to be understood that the invention encompasses all optical isomers, enantiomers and diastereomers.
  • the compounds according to formula (I) can be in the form of the single stereoisomers, i.e. the single enantiomer (the R-enantiomer or the S-enantiomer) and/or diastereomer.
  • the compounds according to formula (I) can also be in the form of a racemic mixture, i.e. an equimolar mixture of enantiomers.
  • Some compounds can exist as a mixture of conformational isomers.
  • the compounds useful in accordance with this invention comprise both mixtures of, and individual, conformational isomers.
  • the present invention is directed to the use of a dual NKi/NK 2 receptor antagonist for the manufacture of a medicament for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
  • Functional dyspepsia refers to pain or discomfort centered in the upper abdomen. Discomfort may be characterized by or combined with upper abdominal fullness, early satiety, bloating or nausea.
  • patients with functional dyspepsia can be divided into two groups: 1- Those with an identifiable pathophysiological or microbiologic abnormality of uncertain clinical relevance (e.g. Helicobacter pylori gastritis, histological duodenitis, gallstones, visceral hypersensitivity, gastroduodenal dysmotility) 2- Patients with no identifiable explanation for the symptoms.
  • Functional dyspepsia can be diagnosed according to the following:
  • alkyl includes straight as well as branched chain C ⁇ .4 alkyl groups, for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t- butyl.
  • One or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom, such as in difluoromethyl or trifluoromethyl.
  • C 2 -C 4 alkynyl is a straight or branched alkynyl group, for example ethynyl.
  • One or more of the hydrogen atoms of the alkynyl group may be substituted for a fluorine atom.
  • C 1 -C 4 hydroxyalkyl is a hydroxyalkyl group comprising 1-4 carbon atoms and a hydroxyl group.
  • One or more of the hydrogen atoms of the hydroxyalkyl group may be substituted for a fluorine atom.
  • alkyl sulfonyl includes C 1 -C 4 alkyl sulfonyl groups, for example methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, i- o propylsulfonyl, n-butylsulfonyl, i-butylsulfonyl, s-butylsulfonyl or t-butylsulfonyl.
  • the dual NK 1 ZNK 2 receptor antagonists are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations.
  • the dual NKiMEC 2 receptor antagonists are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant.
  • the carrier may be in the form of a solid, semi-solid or liquid diluent.
  • Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules.
  • Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
  • Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent.
  • Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
  • Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.
  • the dual NK 1 ZNK 2 receptor antagonists may be administered once or twice daily, depending on the severity of the patient's condition.
  • CHO Kl cells obtained from ATCC are stably transfected with the human NK 2 receptor (hNK 2 R cDNA in pRc/CMV, Invitrogen).
  • the cells are transfected with the cationic lipid reagent LIPOFECT AMINETM (Invitrogen) and selection is performed with Geneticin (G418, Invitrogen) at lmg/ml for the hNK 2 R transfected cells.
  • Single cell clones are collected by aid of Fluorescence Activated Cell Sorter (FACS), tested for functionality in a FLIPR assay (see below), expanded in culture and cryopreserved for future use.
  • FACS Fluorescence Activated Cell Sorter
  • CHO cells stably transfected with human NK 1 receptors originates from AstraZeneca R&D, Wilmington USA.
  • Human NK 1 receptor cDNA obtained from RNA-PCR from lung tissue
  • pRcCMV Invitrogen
  • Transfection is performed by Calcium Phosphate and selection with lmg/ml G418.
  • the CHO cells stably transfected with hNKiR and hNK 2 R are cultured in a humidified incubator under 5% CO 2 , in Nut Mix F12 (HAM) with Glutamax 1, 10% Foetal Bovine Serum (FBS), 1% Penicillin/Streptomycin (PEST) supplemented with 200 ⁇ g/ml Geneticin for the hNKiR and hNK 2 R expressing cells.
  • the cells are grown in Tl 75 flasks and routinely passaged when 70-80% confluent for up to 20-25 passages.
  • NKi/NK 2 receptor mediated increase in intracellular Ca 2+ is assessed by the following procedure:
  • CHO cells stably transfected with human NKi or NK 2 receptors are plated in black walled/clear bottomed 96-w ⁇ ll plates (Costar 3904) at 3.5xlO 4 cells per well and grown for approximately 24h in normal growth media in a 37°C CO 2 -incubator. Before the FLIPR assay the cells of each 96-well plate are loaded with the Ca 2+ sensitive dye Fluo-3 (TEFLABS 0116) at 4 ⁇ M in a loading media consisting of Nut Mix F12
  • HAM HAM with Glutamax I, 22mM HEPES, 2.5mM Probenicid (Sigma P-8761) and 0.04% Pluronic F-127 (Sigma P-2443) for 1 h kept dark in a 37 0 C CO 2 -incubator.
  • the cells are then washed three times in assay buffer (Hanks balanced salt solution (HBSS) containing 2OmM HEPES, 2.5mM Probenicid and 0.1% BSA) using a multi-channel pipette leaving them in 150 ⁇ l at the end of the last wash.
  • assay buffer Horkels balanced salt solution (HBSS) containing 2OmM HEPES, 2.5mM Probenicid and 0.1% BSA
  • IC 5 os are calculated from ten-point concentration-response curves for each compound.
  • pK B - log KB
  • the homogenates are again centrifuged as described above and resuspended in Tris-HCl 5OmM pH 7.4. This centrifugation step is repeated 3 times in total. After the last centrifugation step the pellet is resuspended in Tris-HCl 5OmM and homogenized with Dual Potter, 10 strokes to a homogenous solution, an aliquot is removed for protein determination. Membranes are aliquoted and frozen at -8O 0 C until use.
  • the radioligand binding assay is performed at room temperature in 96-well microtiter plates (No-binding Surface Plates, Corning 3600) with a final assay volume of 200 ⁇ l/well in incubation buffer (5OmM Tris buffer (pH 7.4 RT) containing 0.1 % BSA, 40 mg/L Bacitracin, complete EDTA-free protease inhibitor cocktail tablets 20 pills/L (Roche) and 3mM MnCl 2 ).
  • Competition binding curves are done by adding increasing amounts of the test compound. Test compounds are dissolved and serially diluted in DMSO, final DMSO concentration 1.5 % in the assay.
  • Non-labelled ZD 6021 (a non selective NK- antagonist, lO ⁇ M final cone) is added for measurement of non-specific binding.
  • 50 ⁇ l of 1.5% DMSO (final cone) in incubation buffer is used for total binding.
  • [ 3 H-Sar,Met(O 2 )- Substance P] (4nM final cone) is used in binding experiments on hNKir, [ 3 H-SR48968] (3nM final cone.) for hNK 2 r.
  • 50 ⁇ l radioligand, 3 ⁇ l test compound diluted in DMSO and 47 ⁇ l incubation buffer are mixed with 5-10 ⁇ g cell membranes in lOO ⁇ l incubation buffer and incubated for 30 min at room temperature on a microplate shaker. The membranes are then collected by rapid filtration on Filtermat B(Wallac), presoaked in 0.1% BSA and 0.3% Polyethyleneimine (Sigma P-3143), using a Micro 96 Harvester
  • the compounds useful in accordance with the present invention demonstrated statistically significant antagonistic activity at the NKj receptor within the interval 7-9 for Q the pK ⁇ .
  • the interval for the pKg was 7-9.
  • tested compounds useful in accordance with the present invention have been shown to be dual NKj/ NK2 receptor antagonists.
  • Male Mongolian gerbils (60-80g) are purchased from Charles River, Germany. On arrival, they are housed in groups often, with food and water ad libitium in temperature and 0 humidity-controlled holding rooms. The animals are allowed at least 7 days to acclimatize to the housing conditions before experiments. Each animal is used only once and killed immediately after the experiment by heart punctuation or a lethal overdose of penthobarbital sodium.
  • the gerbils are lightly anaesthetized using isofluoran ⁇ and a small incision is made in the skin over bregma.
  • 10 pmol of ASMSP a selective NKi receptor agonist
  • ASMSP a selective NKi receptor agonist
  • the gastric distension model enables detailed analysis of the physico-mechanical properties of the stomach, e.g. basal gastric tone, threshold for accommodation, accommodation rate, accommodation volume, and maximal gastric volume.
  • basal gastric tone e.g. basal gastric tone
  • threshold for accommodation
  • accommodation rate accommodation rate
  • accommodation volume e.g. maximal gastric volume.
  • WKY Wistar Kyoto
  • SD Sprague Dawley
  • the advantage of the presently used barostat technique compared to other barostat techniques normally used in experimental clinical studies is that it is possible to discriminate between if a compound exerts its effect directly on gastric smooth muscles or if the effect involves the vagal reflex mechanism.
  • the rats are equipped with fistulas chronically implanted into the stomach.
  • a small inflatable plastic bag with a spherical shape is inserted through fistula into the glandular part of the stomach (middle to distal part in the rat).
  • the experiments are performed in conscious rats.
  • a combination of ramp and tonic distension paradigm is used for detailed analysis of the physico-mechanical properties of the stomach. Pressure and volume data collected during experiments are saved for and further analysis.
  • a balloon is inserted into the stomach of the animal and a four phase protocol which includes a start phase, a ramp phase, a tonic phase and an end phase is performed.
  • the pressure applied to the balloon and the corresponding changes to the volume of the balloon are monitored throughout, e.g., using any barostat system known in the art (e.g., see Toma et al, Neurogastroenterol. Mot, 8, 19-28, 1996).
  • a minimum distension pressure e.g., 1 rnmHg
  • a Ramp Phase During this phase the pressure applied to the balloon is increased linearly with a constant increase in pressure.
  • the pressure delivered to the balloon can be between 2-20 mmHg.
  • This phase is then followed by the Tonic Phase.
  • the pressure is kept constant at the maximum pressure.
  • the pressure is dropped to the starting minimum distension pressure and this period is known as the End Phase.
  • the maximum gastric accommodation capacity in the animal following administration of the compound is calculated.
  • a compound of interest will be a compound that alters the maximum gastric accommodation capacity in the animal and this is calculated by determining a difference in the maximum gastric accommodation capacity before and after administration of the compound.
  • the Wistar Kyoto rats (WKY; M&B Denmark) are starved about 8 or 18 hours before each experiment depending on if the experiments are performed in the morning or in the afternoon.
  • a small, inflatable balloon is inserted through the central hole of the fistula into the distal part of stomach under isoflurane anaesthesia (Forene ® , Abbott Scandinavia AB) and fixed in its position through the tightening of the fistula.
  • the balloon has a spherical shape with a wall thickness of about 15 ⁇ m, a non-distensible max diameter of 25 mm and a max volume of about 7 ml.
  • the balloon is connected to a double-lumen polyethylene catheter with an outer diameter of 1.40 mm and a length of about 20 cm.
  • a barostat system maintains the pressure by pumping air into and out of the balloon. After the experiment the balloon and the connecting cable are removed under isoflurane anaesthesia and the animals are returned to their normal cages.
  • Fig 2 The results shown in Fig 2 indicate that (3aR,7aR)-2-[2-(2-methoxyphenyl)ethanimidoyl] ⁇ 7,7-diphenyloctahydro-4H-isoindol-4-one (RP67580), a NK 1 receptor antagonist (commercially available from Tocris) in a dose of 3 ⁇ mol/kg in WKY rats induced an increased gastric volume both during the tonic phase and the ramp phase in addition to an increased maximum gastric volume compared to the control situation. The increased maximum gastric volume is probably due to the increased accommodation rate seen (the slope of volume curve during the tonic phase).

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of dual NK1/NK2 receptor antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.

Description

NOVEL TREATMENT OF GASTROINTESTINAL DISORDERS
Field of the invention
5 The present invention relates to the use of dual NK1ZNK2 receptor antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
Background of the invention
I Q
Functional gastrointestinal disorders, such as functional dyspepsia, can be defined in accordance with Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Mueller-Lissner SA. C. Functional Bowel Disorders and Functional Abdominal Pain. In: Drossman DA, Talley NJ, Thompson WG, Whitehead WE, Coraziarri E, eds. Rome II: 15 Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment. 2 ed. McLean, VA: Degnon Associates, Inc.; 2000:351-432 and Drossman DA, Corazziari E, Talley NJ, Thompson WG and Whitehead WE. Rome II: A multinational consensus document on Functional Gastrointestinal Disorders. Gut 45(Suppl.2), II1-II81.9-1-1999.
2Q The neurokinins, also known as the tachykinins, comprise a class of peptide neurotransmitters which are found in the peripheral and central nervous systems. The three principal tachykinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB). At least three receptor types are known for the three principal tachykinins. Based upon their relative selectivities favouring the agonists SP, NKA and NKB, the receptors 5 are classified as neurokinin 1 (NK1), neurokinin 2 (NK2) and neurokinin 3 (NK3) receptors, respectively.
Functional gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) and functional dyspepsia are characterized by increased visceral sensations manifested as 30 abdominal discomfort or even pain. The tachykinins, which bind to neurokinin (NK) receptors, are present in neurons that transmit signals from the GI tract to the brain. The object of the present invention was to find a new way for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
Outline of the invention
The present invention is directed to the use of dual NKi/NK2 receptor antagonists for the manufacture of a medicament for the treatment of functional gastrointestinal disorders.
One aspect of the present invention is the use of dual NKi/NK2 receptor antagonists for the manufacture of a medicament for the treatment of functional dyspepsia.
Still a further aspect of the present invention is directed to the use of a compound of formula I
Figure imgf000003_0001
for the manufacture of a medicament for treatment of functional gastrointestinal disorders, wherein
Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom;
Rl is hydrogen, hydroxy, Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl; R2 and R3 is each and independently selected from hydrogen, Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, Ci-C4 alkoxy, halogen and cyano, provided that R2 and R3 may not both be hydrogen;
R4 is Ci -C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl;
Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1- naphthyl; 5,6,7,8-tetrahydro-l-naphthyl; quinolinyl; 2,3-dihydro-l,4-benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8-tetrahydroisoquinolinyl;
5 ,6,7, 8-tetrahydroquinazolin-4-yl; 1 -benzo [b] thiophen-7-yl; 1 -benzo [b]thiophen-4-yl; l-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl;
or an enantiomer thereof or any salt thereof.
In a still further aspect of the invention, the functional gastrointestinal disorder is functional dyspepsia.
In one embodiment of the present invention, the heterocyclic ring Het is connected to the rest of the molecule at one of the nitrogen atoms of the ring. Examples of such heterocyclic rings are optionally substituted l,4-dioxa-8-azaspiro[4.5]decano; optionally substituted piperidino; optionally substituted azepano; optionally substituted pyrrolidino; optionally substituted morpholino; optionally substituted oxazepano; optionally substituted thiomorpholino; optionally substituted thiazepano; and optionally substituted piperazino.
In further embodiments of the present invention Het is piperidino optionally substituted with hydroxy, hydroxyalkyl, oxo, methylthio, methylsulfinyl, methylsulfonyl, cyano, 1,3- dioxolan-2-yl, C1-C4 alkoxy, amino optionally mono or disubstituted with C1-C4 alkyl, C3- C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, acylamino optionally N-substituted with Ci- C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, (Ci-C4 alkylsulfonyl)amino optionally N-substituted by Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, one or two fluoro atoms or disubstituted by Ci-C4 alkyl and hydroxy; pyrrolidino optionally substituted at its three position by fluoro, hydroxy or oxo; morpholino or thiomorpholino optionally substituted at its sulfur atom by one or two oxygen; or piperazino optionally substituted at the 4-nitrogen atom by C1-C4 alkyl.
Ar may optionally be substituted at one or more of its carbon atoms by one or more groups independently selected from cyano, halogen, C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, nitro, trifluoromethoxy, difluoromethoxy, trifluoromethyl, Ci-C4 alkylsulfinyl, C]-C4 alkylsulfonyl, Ci-C4 alkylthio, trifluoromethylsulfonyloxy, Ci- C4 alkyl sulfonyl or Ci-C4 acyl.
In one embodiment of the present invention, Ar is phenyl substituted by one or more groups independently selected from cyano, halogen, Ci-C4 allcyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, Ci-C4 alkoxy, nitro, trifluoromethoxy, difluoromethoxy, Ci-C4 alkylsulfinyl, Ci-C4 alkylsulfonyl, Ci-C4 alkylthio, trifluoromethylsulfonyloxy, Cj-C4 alkyl sulfonyl or Ci-C4 acyl.
In a further embodiment of the present invention, Ar is phenyl substituted in its 3- and 5- position by groups independently selected from halogen, Ci-C4 alkyl, Ci-C4 alkoxy, cyano and nitro. Optionally, Ar may additionally also be substituted in its 2- and/or 4-position by a group independently selected from halogen, Ci-C4 alkyl and Ci-C4 alkoxy.
In one embodiment of the present invention, Rl is hydrogen.
In one embodiment of the present invention, R2 and R3 are both chloro or one is fluoro and the other is hydrogen. In a further embodiment of the invention, R2 and R3 are both chloro and attached in the three and four position of the phenyl ring or R2 is fluoro attached in the four position and R3 is hydrogen.
In one embodiment of the present invention, R4 is methyl. In one embodiment of the present invention, the compound of formula I is the S- enantiomer or the racemate. In a further embodiment of the invention, the compound of formula I is the S-enantiomer.
In one embodiment of the present invention, the compound of formula I is the R- enantiomer or the racemate. In a further embodiment of the invention, the compound of formula I is the R-enantiomer.
A further aspect of the invention relates to compounds of formula I, wherein Het is tbiomorpholino, morpholino or oxidothiomorpholino; Rl is H;
R2 is fluoro and R3 is hydrogen, fluoro being preferably in para position; Ar is 3-cyano-5,6,7,8-tetrahydro-l-naphthyl; and R4 is as defined above.
A further aspect of the invention is the use of any of the following compounds for the treatment of functional gastrointestinal disorders, such as functional dyspepsia:
3,5-Dichloro-N-[(21S)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]- N-methylbenzamide;
3,5-Dibromo-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methylbenzamide ;
N-[(2S)-2-(3,4-Dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-355-difluoro- N-methylbenzamide;
N-[(25)-2-(3,4-Dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidrn-l-yl)butyl]-N-methyl-3,5- bis(trifluoromethyl)benzamide; 5-Cyano-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomoφholin-4-ylazetidin-l-yl)butyl]-N- methyl- 1 -benzothiophene-7-carboxamide;
3 -Cyano-N-[(2S)-2-(3 ,4-dichlorophenyl)-4-(3 -thiomorpholin-4-ylazetidin- 1 -yl)butyl]-N- methylbenzamide;
3 -Cyano-N- [(25)-2-(3 ,4-dichloropheny l)-4-(3 -thiomorpholin-4-ylazetidin- 1 -yl)butyl] -N- methyl-5,6,7,8-tetrahydronaphthalene- 1 -carboxamide;
2-Cyano-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomoφholin-4-ylazetidin-l-yl)butyl]-N- methylquinoline-4-carboxamide;
3-Cyano-N-[2-(4-fluorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-N-methyl- 5,6,7,8-tetrahydronaphthalene-l-carboxamide;
N-[2-(4-Fluorophenyl)-4-(3-thiomoφholin-4-ylazetidin-l-yl)butyl]-N-methyl-3,5- bis(trifluoromethyl)benzamide;
7-Chloro-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomoφholin-4-ylazetidin-l-yl)butyl]-N- methyl-2,3-dihydro-l,4-benzodioxine-5-carboxamide;
N- {(25)-2-(3 ,4-Dichlorophenyl)-4-[3 -( 1 -oxidothiomoφholin-4-yl)azetidin- 1 -yl]butyl} -2- methoxy-N-methylquinoline-4-carboxamide;
3-Fluoro-N-[(2.S)-2-(4-fluorophenyl)-4-(3-moφholin-4-ylazetidin-l-yl)butyl]-N-methyl-5- (trifluoromethyl)benzamide;
3 -Cyano-N- {2-(4-fluorophenyl)-4-[3 -(4-hydroxypiperidin- 1 -yl)azetidin- 1 -yljbutyl} -N- methyl-5,6,7,8-tetrahydronaphthalene- 1 -carboxamide; N-[4-[3-(l,4-Dioxa-8-azasρiro[4.5]dec-8-yl)azetidin-l-yl]-2-(4-fluorophenyl)butyl]-iV- methyl-3,5-bis(trifluoromethyl)benzamide;
N-{(26)-2-(3,4-Dichlorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l-yl]butyl}-N- methyl-3,5-bis(trifluoromethyl)benzamide;
iV-{(25)-2-(3,4-Dichlorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l-yl]butyl}-N- methyl-3,5-bis(trifluoromethyl)benzamide;
3 -Cyano-N- {(2S)-2-(3,4-dichlorophenyl)-4-[3-(3-hydroxypyrrolidin- 1 -yl)azetidin- 1 - yljbutyl} -iV-methyl- 1 -naphthamide;
N-{(25f)-2-(4-Fluorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l-yl]butyl}-N-methyl- 3 ,5-bis(trifluoromethyl)benzamide;
3-Cyano-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N-methyl- 5,6,7,8-tetrahydronaphthalene-l-carboxamide;
N- {(25)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin- 1 -yl)azetidin- 1 -yljbutyl} -N-methyl- 3,5-bis(trifluoromethyl)benzamide;
3,5-Dichloro-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methylbenzamide;
3-Cyano-N-[(2,S)-2-(3,4-dichlorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-iV- methyl- 1 -naphthamide;.
3-Cyano-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-N- methyl- 1 -naphthamide; 3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)azetidin- 1 -yljbutyl} -N-methyl- 1 -naphthamide;
3 -Cyano-N- {(2-S)-2-(3,4-dichlorophenyl)-4-[3 -(4-hydroxypiperidin- 1 -yl)azetidin- 1 - 5 yljbutyl} -N-methyl- 1 -naphthamide;
3 -Cyano-N- [2-(4-fluorophenyl)-4-(3 -thiomorpholin-4-ylazetidin- 1 -yl)butyl] -N-methyl- 1 - naphthamide;
i o 3-Cyano-N-[2-(4-cyanophenyl)-4-(3 -thiomorpholin-4-ylazetidin- 1 -yl)butyl] -N-methyl- 1 - naphthamide;
3-Cyano-N-{(21S)-2-(3,4-dichlorophenyl)-4-[3-(l,l-dioxidothiomorpholin-4-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
15
3-Cyano-N- {(2-S)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidm- 1 -yl)azetidin- 1 -yljbutyl} - N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-ethyl-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholm-4-ylazetidin-l-yl)butyl]- 20 5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-[(25)-4-[3-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)azetidin-l-yl]-2-(4- fluorophenyl)butyl]-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
25 3-cyano-N-[(2.S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N-methyl-l- naphthamide;
3-Cyano-N-{(25)-2-(4-fluorophenyl)-4-[3-(l,4-oxazepan-4-yl)azetidin-l-yl]butyl}-N- methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
30 3-Fluoro-N-[(2,S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetid.in-l-yl)butyl]-N-methyl- 5,6,7,8-tetraliydronaphthalene-l-carboxamide;
3,5-Dibromo-N-{(25)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l- yl]butyl}-N-methylbenzatnide;
3-Bromo-N-[(21S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-5-iodo-N- methylbenzamide;
3-Cyano-N-[2-(4-fluoro-2-methylphenyl)-4-(3-morpliolin-4-ylazetidin-l-yl)butyl]-N- methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
6-Cyano-N-[(21S)-2-(4-fluorophenyl)-4-(3-moφholin-4-ylazetidin-l-yl)butyl]-N- methylindane-4-carboxamide;
3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l- yljbutyl} -N-methyl- 1 -naphthamide;
3 -Cyano-N- {2-(4-cyanophenyl)-4-[3-( 1 -oxidothiomorpholin-4-yl)azetidin- 1 -yljbutyl} -N- methyl- 1 -naphthamide;
3,5-Dichloro-N-{(25)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidothiomoφholin-4-yl)azetidin-l- yl]butyl} -N-methylbenzamide;
N- [(2S)-2-(3 ,4-Dichlorophenyl)-4-(3 -oxidothiomorpholin-4-ylazetidin- 1 -yl)butyl] -N- methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-N- {(25)-2-(3 ,4-dichlorophenyl)-4-[3-( 1 -oxidothiomoφholin-4-yl)azetidin- 1 - yl]butyl} -N-methyl-5 ,6,7,8-tetrahydronaphthalene- 1 -carboxamide; 3-Cyano-N-{2-(4-fluorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l-yl]butyl}-N- methyl- 1 -naphthamide;
3-cyano-N-{2-(4-fluorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l-yl]butyl}-N- methyl-5,6,7,8-tetrahydronaphthalene- 1 -carboxamide;
N-{2-(4-Fluorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l-yl]butyl}-N-methyl- 3 , 5 -bis(trifluoromethyl)benzamide ;
3-Cyano-Ν-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(4-oxopiperidin-l-yl)azetidin-l-yl]butyl}- N-methy 1- 1 -naphthamide ;
N- {2-(4-fluorophenyl)-4-[3-(4-oxopiperidin- 1 -yl)azetidin- l-yl]butyl} -N-methyl-3 ,5- bis(trifluoromethyl)benzamide;
3-Cyano-Ν-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
3 -Cyano-N- {2-(4-fluorophenyl)-4- [3 -(4-fluoropiperidin- 1 -yl)azetidin- 1 -yljbutyl} -N- methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-{(2>S)-2-(3,4-dichlorophenyl)-4-[3-(4-methylpiperazin-l-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
N-[(2iS)-4-[3-(4-Acetylpiperazin-l-yl)azetidin-l-yl]-2-(3,4-dichlorophenyl)butyl]-3-cyano- N-methyl- 1 -naphthamide;
3-Cyano-N-[(25)-4-[3-(4-cyanopiperidin-l-yl)azetidin-l-yl]-2-(3,4-dichlorophenyl)butyl]- N-methyl- 1 -naphthamide; or an enantiomer thereof or any salt thereof.
The compounds useful in accordance with the present invention are capable of forming salts with various inorganic and organic acids and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, cyclohexyl sulfamate, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2- hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, palmoate, persulfate, phenylacetate, phosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), and undecanoate. Non-toxic physiologically acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.
Pharmaceutically acceptable salts may be prepared from the corresponding acid in conventional manner. Non-pharmaceutically-acceptable salts may be useful as intermediates and as such are another aspect of the present invention.
Acid addition salts may also be in the form of polymeric salts such as polymeric sulfonates.
The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.
Compounds of formula I have one or more chiral centres, and it is to be understood that the invention encompasses all optical isomers, enantiomers and diastereomers. The compounds according to formula (I) can be in the form of the single stereoisomers, i.e. the single enantiomer (the R-enantiomer or the S-enantiomer) and/or diastereomer. The compounds according to formula (I) can also be in the form of a racemic mixture, i.e. an equimolar mixture of enantiomers.
It is to be understood that the present invention also relates to the use of any and all tautomeric forms of the compounds of formula I.
Some compounds can exist as a mixture of conformational isomers. The compounds useful in accordance with this invention comprise both mixtures of, and individual, conformational isomers.
Consequently, the present invention is directed to the use of a dual NKi/NK2 receptor antagonist for the manufacture of a medicament for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
Functional dyspepsia refers to pain or discomfort centered in the upper abdomen. Discomfort may be characterized by or combined with upper abdominal fullness, early satiety, bloating or nausea. Etiologically, patients with functional dyspepsia can be divided into two groups: 1- Those with an identifiable pathophysiological or microbiologic abnormality of uncertain clinical relevance (e.g. Helicobacter pylori gastritis, histological duodenitis, gallstones, visceral hypersensitivity, gastroduodenal dysmotility) 2- Patients with no identifiable explanation for the symptoms.
Functional dyspepsia can be diagnosed according to the following:
At least 12 weeks, which need not be consecutive within the preceding 12 months of
1- Persistent or recurrent dyspepsia (pain or discomfort centered in the upper abdomen) and
2- No evidence of organic disease (including at upper endoscopy) that is likely to explain the symptoms and 3- No evidence that dyspepsia is exclusively relieved by defecation or associated with the onset of a change in stool frequency or form.
Functional dyspepsia can be divided into subsets based on distinctive symptom patterns, such as ulcer-like dyspepsia, dysmotility-like dyspepsia and unspecified (non-specific) dyspepsia.
Currently existing therapy of functional dyspepsia is largely empirical and directed towards relief of prominent symptoms. The most commonly used therapies still include antidepressants.
Unless stated otherwise, the term "alkyl" includes straight as well as branched chain C\ .4 alkyl groups, for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t- butyl. One or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom, such as in difluoromethyl or trifluoromethyl.
As used herein, C3-C4 cycloalkyl is a cyclic alkyl such as cyclopropyl or cyclobutyl. The cycloalkyl may also be unsaturated. One or more of the hydrogen atoms of the cycloalkyl group may be substituted for a fluorine atom.
As used herein, C2-C4 alkenyl is a straight or branched alkenyl group, for example vinyl. One or more of the hydrogen atoms of the alkenyl group may be substituted for a fluorine atom.
As used herein, C2-C4 alkynyl is a straight or branched alkynyl group, for example ethynyl. One or more of the hydrogen atoms of the alkynyl group may be substituted for a fluorine atom. As used herein, C1-C4 hydroxyalkyl is a hydroxyalkyl group comprising 1-4 carbon atoms and a hydroxyl group. One or more of the hydrogen atoms of the hydroxyalkyl group may be substituted for a fluorine atom.
5 The term "alkoxy" as used herein, unless stated otherwise includes C1-C4 alkoxy groups, for example methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy or t- butoxy. One or more of the hydrogen atoms of the alkoxy group may be substituted for a fluorine atom.
o The term "alkylthio" as used herein, unless stated otherwise includes C1-C4 alkylthio groups, for example methylthio, ethylthio, n-propylthio, i-propylthio, n-butylthio, i- butylthio, s-butylthio or t-butylthio. One or more of the hydrogen atoms of the alkylthio group may be substituted for a fluorine atom.
s In this specification, unless stated otherwise, the term "halogen" includes chloro, bromo, fiuoro and iodo.
In this specification, unless stated otherwise, the term "alkyl sulfonyl" includes C1-C4 alkyl sulfonyl groups, for example methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, i- o propylsulfonyl, n-butylsulfonyl, i-butylsulfonyl, s-butylsulfonyl or t-butylsulfonyl.
In this specification, unless stated otherwise, the term "alkylsulfinyl" includes Ci-C4 alkyl sulfinyl groups, for example methylsulfmyl, ethylsulfmyl, n-propylsulfmyl, i- propylsulfinyl, n-butylsulfinyl, i-butylsulfinyl, s-butylsulfinyl or t-butylsulfinyl. 5
In this specification, unless stated otherwise, the term "acyl" includes C1-C4 acyl groups, for example formyl, acetyl, propionyl, butyryl and isobutyryl.
As used herein, the term "free base" means the compound in its neutral form, i.e. when the o compound is not present as a salt. For the purpose of this invention, the term "antagonist" should be understood as including full antagonists, inverse agonists, non-competitive antagonists or competitive antagonists, as well as partial antagonists, whereby a "partial antagonist" should be understood as a compound capable of partially, but not fully, in-activating the NK-I and NK-2 receptors.
For the purpose of this invention, the term "dual NK-I /NK-2 antagonist" should be understood as including a compound with antagonistic activity at the NKj receptor within the interval 7-9 for the pKβ and within the interval of 7-9 for the pKjg at the NK 2 receptor.
The present invention is directed to the use of any dual NKi/NK2 receptor antagonist that has a therapeutic effect in functional gastrointestinal disorders, such as functional dyspepsia.
The term "therapy" and/or "treatment" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.
The term "therapeutic effect" is defined herein as an effect favourable in the context of the therapy and/or treatment of functional gastrointestinal disorders, such as functional dyspepsia.
The compounds useful in accordance with the present invention can be synthesized as described in WO2004/110344 A2.
Pharmaceutical formulations
For clinical use, the dual NK1ZNK2 receptor antagonists are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations. Thus, the dual NKiMEC2 receptor antagonists are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant. The carrier may be in the form of a solid, semi-solid or liquid diluent.
In the preparation of oral pharmaceutical formulations in accordance with the invention, the dual NKi/NK2 receptor antagonist(s) to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or compressed into tablets.
Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.
In one aspect of the present invention, the dual NK1ZNK2 receptor antagonists may be administered once or twice daily, depending on the severity of the patient's condition.
Pharmacology
Transfection and culturing of cells used in FLIPR and Binding assays
Chinese Hamster Ovary (CHO) Kl cells (obtained from ATCC) are stably transfected with the human NK2 receptor (hNK2R cDNA in pRc/CMV, Invitrogen). The cells are transfected with the cationic lipid reagent LIPOFECT AMINE™ (Invitrogen) and selection is performed with Geneticin (G418, Invitrogen) at lmg/ml for the hNK2R transfected cells. Single cell clones are collected by aid of Fluorescence Activated Cell Sorter (FACS), tested for functionality in a FLIPR assay (see below), expanded in culture and cryopreserved for future use. CHO cells stably transfected with human NK1 receptors originates from AstraZeneca R&D, Wilmington USA. Human NK1 receptor cDNA (obtained from RNA-PCR from lung tissue) is subcloned into pRcCMV (Invitrogen). Transfection is performed by Calcium Phosphate and selection with lmg/ml G418.
The CHO cells stably transfected with hNKiR and hNK2R are cultured in a humidified incubator under 5% CO2, in Nut Mix F12 (HAM) with Glutamax 1, 10% Foetal Bovine Serum (FBS), 1% Penicillin/Streptomycin (PEST) supplemented with 200μg/ml Geneticin for the hNKiR and hNK2R expressing cells. The cells are grown in Tl 75 flasks and routinely passaged when 70-80% confluent for up to 20-25 passages.
Assessing the Activity of Selected test Compounds to Inhibit Human NK1/NK2 Receptor Activation (FLIPR assay)
The activity of a compound useful in accordance with the present invention to inhibit NK]/NK2 receptor activation measured as NKi/NK2 receptor mediated increase in intracellular Ca2+ is assessed by the following procedure:
CHO cells stably transfected with human NKi or NK2 receptors are plated in black walled/clear bottomed 96-wεll plates (Costar 3904) at 3.5xlO4 cells per well and grown for approximately 24h in normal growth media in a 37°C CO2-incubator. Before the FLIPR assay the cells of each 96-well plate are loaded with the Ca2+ sensitive dye Fluo-3 (TEFLABS 0116) at 4μM in a loading media consisting of Nut Mix F12
(HAM) with Glutamax I, 22mM HEPES, 2.5mM Probenicid (Sigma P-8761) and 0.04% Pluronic F-127 (Sigma P-2443) for 1 h kept dark in a 370C CO2-incubator. The cells are then washed three times in assay buffer (Hanks balanced salt solution (HBSS) containing 2OmM HEPES, 2.5mM Probenicid and 0.1% BSA) using a multi-channel pipette leaving them in 150μl at the end of the last wash. Serial dilutions of a test compound in assay buffer (final DMSO concentration kept below 1%) are automatically pipetted by FLIPR (Fluorometric Imaging Plate Reader) into each test well and the fluorescence intensity is recorded (excitation 488 nm and emission 530 nm) by the FLIPR CCD camera for a 2 min pre-incubation period. 50μl of the Substance P (NKi specific) or NKA (NK2 specific) agonist solution (final concentration equivalent to an approximate EC60 concentration) is then added by FLIPR into each well already containing 200μl assay buffer (containing the test compound or vehicle) and the fluorescence is continuously monitored for another 2 min. The response is measured as the peak relative fluorescence after agonist addition and IC5os are calculated from ten-point concentration-response curves for each compound. The IC5os are then converted to pKβ values with the following formula: KB = IC50 / 1+ (EC60 cone, of agonist used in assay / EC50 agonist) pKB = - log KB
Determining the Dissociation Constant (Ki) of compounds for Human NK1/NK2 Receptors (Binding Assay)
Membranes are prepared from CHO cells stably transfected with human NK1 or NK2 receptors according to the following method.
Cells are detached with Accutase® solution, harvested in PBS containing 5% FBS by centrifugation, washed twice in PBS and resuspended to a concentration of 1x108 cells/ml in Tris-HCl 50 mM, KCl 300 mM, EDTA-N2 10 mM pH 7.4 (4°C). Cell suspensions are homogenized with an UltraTurrax 30 s 12.000 rpm. The homogenates are centrifuged at 38.000 x g (40C) and the pellet resuspended in Tris-HCl 50 mM pH 7.4. The homogenization is repeated once and the homogenates are incubated on ice for 45 min. The homogenates are again centrifuged as described above and resuspended in Tris-HCl 5OmM pH 7.4. This centrifugation step is repeated 3 times in total. After the last centrifugation step the pellet is resuspended in Tris-HCl 5OmM and homogenized with Dual Potter, 10 strokes to a homogenous solution, an aliquot is removed for protein determination. Membranes are aliquoted and frozen at -8O0C until use. The radioligand binding assay is performed at room temperature in 96-well microtiter plates (No-binding Surface Plates, Corning 3600) with a final assay volume of 200μl/well in incubation buffer (5OmM Tris buffer (pH 7.4 RT) containing 0.1 % BSA, 40 mg/L Bacitracin, complete EDTA-free protease inhibitor cocktail tablets 20 pills/L (Roche) and 3mM MnCl2). Competition binding curves are done by adding increasing amounts of the test compound. Test compounds are dissolved and serially diluted in DMSO, final DMSO concentration 1.5 % in the assay. 50μl Non-labelled ZD 6021 (a non selective NK- antagonist, lOμM final cone) is added for measurement of non-specific binding. For total binding, 50μl of 1.5% DMSO (final cone) in incubation buffer is used. [3H-Sar,Met(O2)- Substance P] (4nM final cone) is used in binding experiments on hNKir, [3H-SR48968] (3nM final cone.) for hNK2r. 50μl radioligand, 3μl test compound diluted in DMSO and 47μl incubation buffer are mixed with 5-10μg cell membranes in lOOμl incubation buffer and incubated for 30 min at room temperature on a microplate shaker. The membranes are then collected by rapid filtration on Filtermat B(Wallac), presoaked in 0.1% BSA and 0.3% Polyethyleneimine (Sigma P-3143), using a Micro 96 Harvester
5 (Skatron Instruments, Norway), Filters are washed by the harvester with ice-cold wash buffer (5OmM Tris-HCl, pH 7.4 at 4°C, containing 3mM MnCl2) and dried at 500C for 30- 60 min. Meltilex scintillator sheets are melted on to filters using a Microsealer (Wallac, Finland) and the filters are counted in a β-Liquid Scintillation Counter (1450 Microbeta, Wallac, Finland). Q The Kj value for the unlabeled ligand is calculated using the Cheng-Prusoff equation (Biochem. Pharmacol. 22:3099-3108, 1973): where L is the concentration of the radioactive ligand used and Kd is the affinity of the radioactive ligand for the receptor, determined by saturation binding. Data is fitted to a four-parameter equation using Excel Fit.
Figure imgf000021_0001
)
Results
In general, the compounds useful in accordance with the present invention demonstrated statistically significant antagonistic activity at the NKj receptor within the interval 7-9 for Q the pKβ. For the NK2 receptor the interval for the pKg was 7-9.
Thus, the tested compounds useful in accordance with the present invention have been shown to be dual NKj/ NK2 receptor antagonists.
5
Biological evalution
Gerbil Foot Tap (NKi specific test model)
Male Mongolian gerbils (60-80g) are purchased from Charles River, Germany. On arrival, they are housed in groups often, with food and water ad libitium in temperature and 0 humidity-controlled holding rooms. The animals are allowed at least 7 days to acclimatize to the housing conditions before experiments. Each animal is used only once and killed immediately after the experiment by heart punctuation or a lethal overdose of penthobarbital sodium.
Gerbils are anaesthetized with isoflurane. Potential CNS-peπneable NKl receptor antagonists are administered intraperitoneally, intravenously or subcutaneously. The compounds are given at various time points (typically 30-120 minutes) prior to stimulation with agonist.
The gerbils are lightly anaesthetized using isofluoranε and a small incision is made in the skin over bregma. 10 pmol of ASMSP, a selective NKi receptor agonist, is administered icv in a volume of 5 μl using a Hamilton syringe with a needle 4 mm long. The wound is clamped shut and the animal is placed in a small plastic cage and allowed to wake up. The cage is placed on a piece of plastic tubing filled with water and connected to a computer via a pressure transducer. The number of hind feet taps is recorded.
Fecal pellet output (NK2 specific test model)
The in vivo effect (NK2) of the compounds of formula I can be determined by measuring NK2 receptor agonist-induced fecal pellet output using gerbil as described in e.g. The Journal of Pharmacology and Experimental Therapeutics (2001) 559-564.
Biological evaluation Methods An in vivo gastric distension model is used as a model for functional gastrointestinal disorders, in particular for functional dyspepsia (Bayati A, Astin M, Ekman C, Mattsson H. Wistar Kyoto rats have impaired gastric adaptive accommodation in response to gastric distension. Gastroenterology 2003; 124 (4, suppl 1): W1471 (abstract)).
The gastric distension model enables detailed analysis of the physico-mechanical properties of the stomach, e.g. basal gastric tone, threshold for accommodation, accommodation rate, accommodation volume, and maximal gastric volume. By using the same model in both rats and humans it has been found that the gastric volume responses is very similar in the rat glandular stomach to that in human proximal stomach. Furthermore, it has been shown that patients with Functional Dyspepsia as well as Wistar Kyoto (WKY) rats have an impaired gastric adaptive response and also a lower total gastric volume as compared to healthy subjects and Sprague Dawley (SD) rats, respectively. In addition, the method has shown to be reproducible and reliable. Moreover, the advantage of the presently used barostat technique compared to other barostat techniques normally used in experimental clinical studies is that it is possible to discriminate between if a compound exerts its effect directly on gastric smooth muscles or if the effect involves the vagal reflex mechanism.
The rats are equipped with fistulas chronically implanted into the stomach. During gastric experiments, a small inflatable plastic bag with a spherical shape is inserted through fistula into the glandular part of the stomach (middle to distal part in the rat). The experiments are performed in conscious rats. For detailed analysis of the physico-mechanical properties of the stomach, a combination of ramp and tonic distension paradigm is used. Pressure and volume data collected during experiments are saved for and further analysis.
In order to determine an animal's maximum gastric accommodation capacity, a balloon is inserted into the stomach of the animal and a four phase protocol which includes a start phase, a ramp phase, a tonic phase and an end phase is performed. The pressure applied to the balloon and the corresponding changes to the volume of the balloon are monitored throughout, e.g., using any barostat system known in the art (e.g., see Toma et al, Neurogastroenterol. Mot, 8, 19-28, 1996).
During the start phase a minimum distension pressure, e.g., 1 rnmHg, is applied to the balloon until base line values are obtained. This is followed by a Ramp Phase. During this phase the pressure applied to the balloon is increased linearly with a constant increase in pressure. The pressure delivered to the balloon can be between 2-20 mmHg. This phase is then followed by the Tonic Phase. During the tonic phase the pressure is kept constant at the maximum pressure. Finally the pressure is dropped to the starting minimum distension pressure and this period is known as the End Phase.
To determine if an agent, e.g., a compound is useful in the treatment of FD, the maximum gastric accommodation capacity in the animal following administration of the compound is calculated. A compound of interest will be a compound that alters the maximum gastric accommodation capacity in the animal and this is calculated by determining a difference in the maximum gastric accommodation capacity before and after administration of the compound.
The Wistar Kyoto rats (WKY; M&B Denmark) are starved about 8 or 18 hours before each experiment depending on if the experiments are performed in the morning or in the afternoon. A small, inflatable balloon is inserted through the central hole of the fistula into the distal part of stomach under isoflurane anaesthesia (Forene®, Abbott Scandinavia AB) and fixed in its position through the tightening of the fistula. The balloon has a spherical shape with a wall thickness of about 15 μm, a non-distensible max diameter of 25 mm and a max volume of about 7 ml. The balloon is connected to a double-lumen polyethylene catheter with an outer diameter of 1.40 mm and a length of about 20 cm. The inner lumen diameter of the catheter was about 0.58 mm. The animals are placed in a specially designed Bollmann cage, with an inner diameter of 60 mm for females and 70 mm for males. The catheter is then, via a pressure transducer, connected to a barostat system.
A barostat system maintains the pressure by pumping air into and out of the balloon. After the experiment the balloon and the connecting cable are removed under isoflurane anaesthesia and the animals are returned to their normal cages.
A combination of ramp and tonic distension is used in all the experiments. The protocol starts with a minimum distension pressure of 1 mrnHg and continues for 20 min in order to collect base line values. The pressure is then increased by a velocity of 1-4 mmHg/min for 10 min to a maximum pressure of 10-20 mmHg (ramp phase). The barostat then keeps the pressure at the maximum pressure for 10 more min (tonic phase). After the tonic phase the pressure drops to the minimum distension pressure of 1 mmHg in about Is. The pressure is then kept at this level for another 20-minute period.
Results
The results shown in Fig 1 show that (S)-N-methyl-N-(4-(4-acetylamino-4-phenyl piperidino)-2-(3,4-dichlorophenyl)butyl benzamide) (SR48968), a NK2 receptor antagonist (can be synthesized as described in Bioorganic & Medicinal Chemistry Letters 1993, 3:5, 925-930) in a dose of 10 μmol/kg in WKY rats induced an increased gastric volume both during the tonic phase and the ramp phase in addition to an increased maximum gastric volume compared to the control situation. The increased maximum gastric volume is probably due to the increased accommodation rate seen (the slope of volume curve during the tonic phase). These results thus conclude that (S)-N-methyl-N-(4-(4-acetylamino-4- phenyl piperidino)-2-(3,4-dichlorophenyl)butyl benzamide) increases the accommodation capacity in WKY rats.
The results shown in Fig 2 indicate that (3aR,7aR)-2-[2-(2-methoxyphenyl)ethanimidoyl]~ 7,7-diphenyloctahydro-4H-isoindol-4-one (RP67580), a NK1 receptor antagonist (commercially available from Tocris) in a dose of 3 μmol/kg in WKY rats induced an increased gastric volume both during the tonic phase and the ramp phase in addition to an increased maximum gastric volume compared to the control situation. The increased maximum gastric volume is probably due to the increased accommodation rate seen (the slope of volume curve during the tonic phase). The conclusion is thus, that (3aR,7aR)-2-[2- (2-methoxyphenyl)ethanimidoyl]-7,7-diphenyloctahydro-4H-isoindol-4-one increases the accommodation capacity in WKY rats.

Claims

Claims
1. Use of a dual NK1ZNK2 receptor antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the treatment of a functional gastrointestional disorder.
2. Use according to claim 1, wherein the functional gastrointestinal disorder is functional dyspepsia.
3. Use according to claim 1 or 2, wherein the dual NKi /NK2 receptor antagonists is a compound of formula I
Figure imgf000026_0001
wherein
Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom;
Rl is hydrogen, hydroxy, C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl;
R2 and R3 is each and independently selected from hydrogen, Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, Ci-C4 alkoxy, halogen and cyano, provided that R2 and R3 may not both be hydrogen; R4 is Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl;
Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1- naphthyl; 5,6,7,8-tetrahydro-l-naphthyl; quinolinyl; 2,3-dihydro-l,4- benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8- tetrahydroisoquinolinyl; 5,6,7,8-tetrahydroquinazolin-4-yl; 1 -benzo[b]thiophen-7- yl; l-benzo[b]thiophen-4-yl; l-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or an enantiomer thereof or any salt thereof.
4. Use according to claim 3, wherein
Het is an optionally substituted 4, 5, 6 or 7-membered heterocyclic ring containing one or more nitrogen atoms;
Rl is hydrogen, hydroxy or C]-C4 alkyl;
R2 and R3 are independently hydrogen, Ci-C4 alkoxy, halogen, CF3 or cyano, provided that both are not hydrogen;
R4 is Ci-C4 alkyl;
Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1- naphthyl; 5,6,7,8-tetrahydro-l-naphthyl; quinolinyl; 2,3-dihydro-l,4- benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8- tetrahydroisoquinolinyl; 5,6,7, 8-tetrahydroquinazolin-4-yl; l-benzo[b]thiophen-
7-yl; l-benzo[b]thiophen-4-yl; l-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or an enantiomer thereof or any salt thereof.
5. Use according to claim 4, wherein Het is piperidino substituted with hydroxy, hydroxyalkyl, oxo, methylthio, methylsulfinyl, methylsulfonyl, cyano, l,3-dioxolan-2-yl, C1-C4 alkoxy, amino optionally mono or disubstituted with Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, acylamino optionally N-substituted with Ci-C4 alkyl, C3-
5 C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, (C1-C4 alkylsulfonyl)amino optionally N-substituted by C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, one or two fluoro atoms or disubstituted by Ci-C4 alkyl and hydroxyl; or Het is morpholino or thiomorpholino optionally substituted at its sulfur atom by one or two oxygen; or o Het is piperazino optionally substituted at the 4-nitrogen atom by Ci-C4 alkyl, C2-
C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl, Ci-C4 alkyl sulfonyl or Cj-C4 acyl;
Rl is hydrogen;
R2 is fluoro attached in the four position; s R3 is hydrogen;
R4 is Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl;
Ar is phenyl substituted in its 3- and 5-position by groups independently selected from halogen, Cj-C4 alkyl, Ci-C4 alkoxy, cyano and nitro; 0 or an enantiomer thereof or any salt thereof.
6. Use according to claim 1 wherein the dual NK-l/NK-2 receptor antagonist is selected from
3,5-Dichloro-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomoφholin-4-ylazetidin-l- 5 yl)butyl]-N-methylbenzamide;
3,5-Dibromo-N-[(21S)-2-(4-fiuorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]- N-methylbenzamide;
o N-[(2S)-2-(3,4-Dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-3,5- difluoro-iV-methylbenzamide; N-[(2.S)-2-(3,4-Dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-N- methyl-3,5-bis(trifluoromethyl)benzamide;
5-Cyano-iV-[(2)S)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methyl-l-benzothiophene-7-carboxamide;
3-Cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-(3-thiomoφholin:4-ylazetidin-l- yl)butyl]-N-methylbenzamide;
3-Cyano-N-[(2.S)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
2-Cyano-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methylquinoline-4-carboxamide;
3 -Cyano-N- [2-(4-fluorophenyl)-4-(3 -thiomoφholin-4-ylazetidin- 1 -yl)butyl] -N- methyl-5,6,7,8-tetrahydronaphthalene- 1 -carboxamide;
N- [2-(4-Fluorophenyl)-4-(3 -thiomorpholin-4-ylazetidin- 1 -yl)buty 1] -N-methyl-3 , 5- bis(trifluoromethyl)benzamide;
7-Cliloro-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methyl-2,3-dihydro-l,4-benzodioxine-5-carboxamide;
N- { (25)-2-(3 ,4-Dichlorophenyl)-4- [3 -( 1 -oxidothiomorpholin-4-yl)azetidin- 1 - yl]butyl}-2-methoxy-N-methylquinoline-4-carboxamide;
3-Fluoro-N-[(25)-2-(4-fluorophenyl)-4-(3-morρholin-4-ylazetidin-l-yl)butyl]-N- methyl-5-(trifluoromethyl)benzamide; 3-Cyano-N-{2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l- yljbutyl} -N-methyl-5 ,6,7,8-tetrahydronaphthalene- 1 -carboxamide;
N-[4-[3-(l,4-Dioxa-8-azasρiro[4.5]dec-8-yl)azetidin-l-yl]-2-(4- fluorophenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)benzamide;
N- {(25)-2-(3 ,4-Dichlorophenyl)-4- [3-(4-fluoropiperidin- 1 -yl)azetidin- 1 -yl]butyl} - N-methyl-3,5-bis(trifluoromethyl)benzamide;
N-{(2-S)-2-(3,4-Dichlorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l- yl]butyl}-N-methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(3-hydroxypyrrolidin-l-yl)azetidin- 1 -yl]butyl} -N-methyl- 1 -naphthamide;
N-{(25)-2-(4-Fluorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l-yl]butyl}-N- methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
N-{(25)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l-yl]butyl}-N- methyl-3,5-bis(trifluoromethyl)benzamide;
3,5-Dichloro-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]- N-methylbenzamide;
3-Cyano-N-[(21S)-2-(3,4-dichlorophenyl)-4-(3-morρholin-4-ylazetidin-l-yl)butyl]- N-methyl- 1 -naphthamide; 3-Cyano-N-[(21S)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methyl- 1 -naphthamide;
3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(l,4-dioxa-8-azasρiro[4.5]dec-8- yl)azetidin- 1 -yl]butyl} -TV-methyl- 1 -naphthamide;
3-Cyano-iV-{(21S)-2-(3,4-dichlorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin- 1 -yljbutyl} -iV-methyl- 1 -naphthamide;
3 -Cyano-N- [2-(4-fluorophenyl)-4-(3 -thiomorpholin-4-ylazetidin- 1 -yl) butyl] -N- methyl- 1 -naphthamide;
3-Cyano-iV-[2-(4-cyanophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]~N- methyl- 1 -naphthamide;
3-Cyano-N-{(25)-2-(3,4-dichlorophenyl)-4-[3-(l,l-dioxidothiomorpholin-4- yl)azetidin- 1 -yl]butyl} -JV-methyl- 1 -naphthamide;
3-Cyano-N- {(2.S)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin- 1 -yl)azetidin- 1 - yl]butyl}-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-ethyl-N-[(2,S)-2-(4-fluorophenyl)-4-(3-moφholin-4-ylazetidin-l- yl)butyl]-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-[(2,S)-4-[3-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)azetidin-l-yl]-2-(4- fluorophenyl)butyl]-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-cyano-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methyl- 1 -naphthamide; 3-Cyano-N- {(25)-2-(4-fluorophenyl)-4-[3-(l ,4-oxazepan-4-yl)azetidin- 1 - yl]butyl}-iV-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Fluoro-iV-[(21S)-2-(4-fluorophenyl)-4-(3-morpholm-4-ylazetidin-l-yl)butyl]-N- methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3,5-Dibromo-N-{(25)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin- 1 -yl]butyl} -N-metliylbenzamide;
3-Bromo-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-5- iodo-N-methylbenzamide;
3-Cyano-N-[2-(4-fluoro-2-methylphenyl)-4-(3-moφholin-4-ylazetidin-l- yl)butyl]-iV-methyl-5,6,7,8-tetraliydronaphthalene-l-carboxamide;
6-Cyano-N-[(25)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methylindane-4-carboxamide ;
3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidothiomorpholin-4- yl)azetidin- 1 -yl]butyl} -N-methyl- 1 -naphthamide;
3-Cyano-N-{2-(4-cyanophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
3 ,5-Dichloro-N- {(25)-2-(3 ,4-dichlorophenyl)-4- [3 -( 1 -oxidothiomorpholin-4- yl)azetidin- 1 -yl]butyl} -iV-methylbenzamide;
N-[(2S)-2-(3,4-Dichlorophenyl)-4-(3-oxidothiomoφholin-4-ylazetidin-l- yl)butyl]-N-methyl-3 ,5-bis(trifluoromethyl)benzamide; 3-Cyano-N-{(25)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidothiomoφholin-4- yl)azetidin- 1 -yljbutyl} -N-methyl-5 ,6,7,8-tetrahydronaphthalene- 1 -carboxamide;
3 -Cyano-N- {2-(4-fluorophenyl)-4- [3 -( 1 -oxidothiomorpholin-4-yl)azetidin- 1 - yl]butyl} -iV-methyl- 1 -naphthamide;
3-cyano-N-{2-(4-fluorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l- yl]butyl}-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxainide;
N-{2-(4-Fluorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetJdin-l-yl]butyl}-iV- methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-Ν-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(4-oxopiperidin-l-y])azetidin-l- yljbutyl} -N-methyl- 1 -naphthamide;
N-{2-(4-fluorophenyl)-4-[3-(4-oxopiperidin-l-yl)azetidin-l-yl]butyl}-7V-methyl- 3,5-bis(trifluoromethyl)benzamide;
3-Cyano-Ν-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
3 -Cyano-N- {2-(4-fluorophenyl)-4- [3 -(4-fluoropiperidin- 1 -yl)azetidin- 1 -yl]butyl} - N-methyl-Sjό^jS-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-{(26)-2-(3,4-dichlorophenyl)-4-[3-(4-methylpiperazin-l-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
N-[(21S)-4-[3-(4-Acetylpiperazin-l-yl)azetidin-l-yl]-2-(3,4-dichlorophenyl)butyl]- 3-cyano-N-methyl-l-naphthamide; 3-Cyano-N-[(25)-4-[3-(4-cyanopiperidin-l-yl)azetidin-l-yl]-2-(3,4- dichlorophenyl)butyl]-N-methyl- 1 -naphthamide; or an enantiomer thereof or any salt thereof.
7. A method for the treatment of a functional gastrointestinal disorder whereby a pharmaceutically and pharmacologically effective amount of a dual NK1ZNK2 receptor antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment.
8. The method according to claim 7, wherein the functional gastrointestinal disorder is functional dyspepsia.
9. A method according to claim 7 or 8, wherein the dual NKi/NK2 receptor antagonist is a compound of formula I
Figure imgf000034_0001
wherein
Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom;
Rl is hydrogen, hydroxy, Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl; R2 and R3 is each and independently selected from hydrogen, Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, halogen and cyano, provided that R2 and R3 may not both be hydrogen;
R4 is C1-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl;
Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1- naphthyl; 5,6,7,8-tetrahydro-l-naphthyl; quinolinyl; 2,3-dihydro-l,4- benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8- tetrahydroisoquinolinyl; 5,6,7,8-tetrahydroquinazolin-4-yl; 1 -benzo[b]thiophen-7- yl; l-benzo[b]thiophen-4-yl; l-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or an enantiomer thereof or any salt thereof.
10. A method according to claim 9, wherein
Het is an optionally substituted 4, 5, 6 or 7-membered heterocyclic ring containing one or more nitrogen atoms;
Rl is hydrogen, hydroxy or C1-C4 alkyl;
R2 and R3 are independently hydrogen, Ci-C4 alkoxy, halogen, CF3 or cyano, provided that both are not hydrogen;
R4 is C1-C4 alkyl;
Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1- naphthyl; 5,6,7,8-tetrahydro-l-naphthyl; quinolinyl; 2,3-dihydro-l,4- benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8- tetrahydroisoquinolinyl; 5,6,7,8-tetrahydroquinazolin-4-yl; l-benzo[b]thiophen- 7-yl; l-benzo[b]thiophen-4-yl; l-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or an enantiomer thereof or any salt thereof.
11. A method according to claim 9, wherein
Het is piperidino substituted with hydroxy, hydroxyalkyl, oxo, methylthio, methylsulfinyl, methylsulfonyl, cyano, l,3-dioxolan-2-yl, C1-C4 alkoxy, amino optionally mono or disubstituted with Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, acylamino optionally N-substituted with Ci-C4 alkyl, C3- C4 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, (Ci-C4 alkylsulfonyl)amino
. optionally N-substituted by Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl, C2-C4. alkynyl, one or two fluoro atoms or disubstituted by Ci-C4 alkyl and hydroxyl; or Het is morpholmo or thiomorpholino optionally substituted at its sulfur atom by one or two oxygen; or Het is piperazino optionally substituted at the 4-nitrogen atom by Ci-C4 alkyl, C2-
C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl, Ci-C4 alkyl sulfonyl or Ci-C4 acyl;
Rl is hydrogen;
R2 is fluoro attached in the four position; R3 is hydrogen;
R4 is Ci-C4 alkyl, C3-C4 cycloalkyl, C2-C4 alkenyl or C2-C4 alkynyl;
Ar is phenyl substituted in its 3- and 5-position by groups independently selected from halogen, Ci-C4 alkyl, Ci-C4 alkoxy, cyano and nitro; or an enantiomer thereof or any salt thereof.
12. A method according to claim 9, wherein the dual NK-l/NK-2 receptor antagonist is selected from
3,5-Dichloro-iV-[(2θ)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-iV-methylbenzamide; 3,5-Dibromo-N-[(25}-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]- N-methylbenzamide;
N-[(2S)-2-(3,4-Dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-3,5- difluoro-N-methylbenzamide;
N-[(25)-2-(3,4-Dichlorophenyl)-4-(3-thiomorρholin-4-ylazetidin-l-yl)butyl]-N- methyl-3,5-bis(trifluoromethyl)benzamide;
5-Cyano-N-[(25)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-iV"-methyl-l-benzothiophene-7--carboxamide;
3-Cyano-iV-[(2S)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methylbenzamide;
3 -Cyano-N- [(26)-2-(3 ,4-dichlorophenyl)-4-(3 -thiomorpholin-4-y lazetidin- 1 - yl)butyl]-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
2-Cyano-iV-[(2,S)-2-(3,4-dichlorophenyl)-4-(3-tliiomorpholin-4-ylazetidin-l- yl)butyl] -N-methylquinoline-4-carboxaniide;
3-Cyano-iV-[2-(4-fluorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-N- methyl-5,6,7,8-tefrahydronaphthalene-l-carboxamide;
N-[2-(4-Fluorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-N-methyl-3,5- bis(trifluoromethyl)benzamide;
7-Chloro-N-[(2-S)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl]-N-methyl-2,3-dihydro-l,4-benzodioxine-5-carboxamide; N- {(2S)-2-(3 ,4-Dichlorophenyl)-4-[3 -(I -oxidothiomorpholin-4-yl)azetidin- 1 - yl]butyl}-2-methoxy-N-methylquinoline-4-carboxamide;
3-Fluoro-N-[(2.S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methyl-5-(trifluoromethyl)benzamide;
3-Cyano-N-{2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l- yl]butyl}-iV-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
N-[4-[3--(l,4-Dioxa-8-azaspiro[4.5]dec-8-yl)azetidin-l-yl]-2-(4- fluoiOphenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)benzamide;
N-{(25)-2-(3,4-Dichlorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l-yl]butyl}- iV-methyl-3,5-bis(trifluoromethyl)benzamide;
N-{(25)-2-(3,4-Dichlorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l- yl]butyl}-N-methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(3-hydroxypyrrolidin-l-yl)azetidin- 1 -yl]butyl} -N-methyl- 1 -naphthamide ;
N-{(25)-2-(4-Fluorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l-yl]butyl}-N- methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-N-[(25)-2-(4-fluorophenyl)-4-(3-moφholin-4-ylazetidiα- 1 -yl)butyl]-N- methyl-5 ,6,7,8-tetrahydronaphthalene- 1 -carboxamide;
N-{(2-S)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l-yl]butyl}-iV- methyl-3,5-bis(trifluoromethyl)benzamide; 3,5-Dichloro-iV-[(2-S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]- N-methylbenzamide;
3-Cyano-N-[(2.S)-2-(3,4-dichlorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]- N-methyl- 1-naphthamide;
3-Cyano-N-[(26)-2-(3,4-dichlorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l- yl)butyl] -N-methy 1- 1 -naphthamide ;
3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(l,4-dioxa-8-azaspiro[4.5]dec-8- yl)azetidin- 1 -yl]butyl} -N-methyl- 1 -naphihamide;
3-Cyano-N-{(2iS)-2-(3,4-dichlorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin- 1 -yl]butyl} -N-methyl- 1 -naphthamide;
3-Cyano-N-[2-(4-fluorophenyl)-4-(3-thiomorpholin-4-ylazetidin-l-yl)butyl]-N- methyl- 1 -naphthamide;
3 -Cyano-N- [2-(4-cyanopheny l)-4-(3 -thiomoipholin-4-ylazetidin- 1 -yl)butyl] -N- methyl- 1 -naphthamide;
3-Cyano-N-{(25)-2-(3,4-dichlorophenyl)-4-[3-(l,l-dioxidothiomoφholin-4- yl)azetidin- 1 -yl]butyl} -N-methyl- 1 -naphthamide;
3-Cyano-N-{(25)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin-l- yl]butyl}-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-ethyl-N-[(2JS)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l- yl)butyl]-5,6,7,8-tetrahydronaphthalene-l-carboxamide; 3-Cyano-N-[(2,S)-4-[3-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)azetidm-l-yl]-2-(4- fluorophenyl)butyl]-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-cyano-N-[(2,S)-2-(4-fluoroplienyl)-4-(3-mθφholin-4-ylazetidin-l-yl)butyl]-N- 5 methyl- 1-naphthamide;
3-Cyano-N- {(2S)-2-(4-fluorophenyl)-4-[3-(l ,4-oxazepan-4-yl)azetidin- 1 - yl]butyl}-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
i o 3 ~Fluoro-N-[(25)-2-(4-fluorophenyl)-4-(3 -morpholin-4-ylazetidin- 1 -yl)buty I]-N- methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3,5-Dibromo-N-{(25)-2-(4-fluorophenyl)-4-[3-(4-hydroxypiperidin-l-yl)azetidin- 1 -yl]butyl} -N-methylbenzamide;
15
3-Bromo-N- [(21S)-2-(4-fluorophenyl)-4-(3 -morpholin-4-ylazetidin- 1 -yl)butyl] -5- iodo-N-methylbenzamide;
3-Cyano-N-[2-(4-fluoro-2-methylphenyl)-4-(3-morpholin-4-ylazetidin-l- 20 yl)butyl]-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
6-Cyano-N-[(21S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-l-yl)butyl]-N- methylindane-4-carboxamide ;
25 3-Cyano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidothiomorpholin-4- yl)azetidin- l-yl]butyl} -N-methyl- 1 -naphthamide;
3-Cyano-N- {2-(4-cyanophenyl)-4-[3-( 1 -oxidothiomorpholin-4-yl)azetidin- 1 - yl]butyl} -N-methyl- 1 -naphthamide;
30 3,5-Dichloro-N-{(2iS)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidotliiomoφholm-4- yl)azetidin-l-yl]butyl}-N-methylbenzamide;
N-[(2S)-2-(3,4-Dichlorophenyl)-4-(3-oxidothiomorpholin-4-ylazetidin-l- yl)butyl]-N-methyl-3 ,5-bis(trifluoromethyl)benzamide;
3-Cyano-N-{(25)-2-(3,4-dichlorophenyl)-4-[3-(l-oxidothiomorpholin-4- yl)azetidin-l-yl]butyl}-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
3-Cyano-N-{2-(4-fluorophenyl)-4-[3-(l-oxidothiomorpholin-4-yl)azetidin-l- yljbutyl} -N-methyl- 1 -naphthamide ;
3-cyano-N-{2-(4-fluorophenyl)-4-[3-(l-oxidothiomorpliolm-4-yl)azetidin-l- yl]butyl}-N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide;
N- {2-(4-Fluorophenyl)-4-[3 -( 1 -oxidothiomorpholin-4-yl)azetidin- 1 -yljbutyl} -N- methyl-3,5-bis(trifluoromethyl)benzamide;
3-Cyano-Ν-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(4-oxopiperidin-l-yl)azetidin-l- yljbutyl} -N-methyl- 1 -naphthamide;
N-{2-(4-fluorophenyl)-4-[3-(4-oxopiperidin-l-yl)azetidin-l-yl]butyl}-N-methyl- 3,5-bis(trifluoromethyl)benzamide;
3-Cyano-Ν-{(2S)-2-(3,4-dichlorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l- yl]butyl} -N-methyl- 1 -naphthamide;
3-Cyano-N-{2-(4-fluorophenyl)-4-[3-(4-fluoropiperidin-l-yl)azetidin-l-yl]butyl}- N-methyl-5,6,7,8-tetrahydronaphthalene-l-carboxamide; 3-Cyano-N-{(2θ)-2-(3,4-dichlorophenyl)-4-[3-(4-methylpiperazin-l-yl)azetidin-l- yljbutyl} -iV-methyl- 1 -naphthamide;
N-[(2.S)-4-[3-(4-Acetylpiperazin-l-yl)azetidin-l-yl]-2-(3,4-dichlorophenyl)butyl]- 3 -cy ano-N-methyl- 1 -naphthamide ;
3-Cyano-N-[(2lS)-4-[3-(4-cyanopiperidin-l-yl)azetidin-l-yl]-2-(3,4- dichlorophenyl)butyl]-N-methyl-l-naphthamide; or an enantiomer thereof or any salt thereof.
PCT/SE2005/001866 2004-12-09 2005-12-07 Novel treatment of gastrointestinal disorders Ceased WO2006062478A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0403005A SE0403005D0 (en) 2004-12-09 2004-12-09 New use
SE0403005-2 2004-12-09

Publications (1)

Publication Number Publication Date
WO2006062478A1 true WO2006062478A1 (en) 2006-06-15

Family

ID=33550627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/001866 Ceased WO2006062478A1 (en) 2004-12-09 2005-12-07 Novel treatment of gastrointestinal disorders

Country Status (2)

Country Link
SE (1) SE0403005D0 (en)
WO (1) WO2006062478A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470816B2 (en) 2007-12-03 2013-06-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365602B1 (en) * 1998-07-10 2002-04-02 Astra Zeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
US6403601B1 (en) * 1998-12-09 2002-06-11 Astrazeneca Ab N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
US6500818B1 (en) * 1998-10-07 2002-12-31 Astrazeneca Ab Naphthalenecarboxamides as tachykinin receptor antagonists
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
WO2004110344A2 (en) * 2003-06-13 2004-12-23 Astrazeneca Ab New azetidine compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365602B1 (en) * 1998-07-10 2002-04-02 Astra Zeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
US6500818B1 (en) * 1998-10-07 2002-12-31 Astrazeneca Ab Naphthalenecarboxamides as tachykinin receptor antagonists
US6403601B1 (en) * 1998-12-09 2002-06-11 Astrazeneca Ab N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
WO2004110344A2 (en) * 2003-06-13 2004-12-23 Astrazeneca Ab New azetidine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MACKENZIE A.R. ET AL: "4-Amino-2-(aryl)-butylbenzamides and Their Conformationally Constrained Analogues. Potent Antagonists of the Human Neurokinin-2 (NK2) Receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, 2003, pages 2211 - 2215 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470816B2 (en) 2007-12-03 2013-06-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof

Also Published As

Publication number Publication date
SE0403005D0 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
RU2535667C2 (en) Enantiomers of spiro-oxindole compounds and using them as therapeutic agents
PL211333B1 (en) Compound hydrate or solvate
TWI729443B (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
TW200902026A (en) Agents for treating disorders involving modulation of ryanodine receptors
EP2184278A1 (en) P2x4 receptor antagonist
JP2007509140A (en) Novel tetrahydrospiro {piperidine-2,7'-pyrrolo [3,2-b] pyridine derivatives and novel indole derivatives useful in the treatment of diseases associated with 5-HT6 receptors
JP5331001B2 (en) 1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as a CB1 receptor modulator
JP5744203B2 (en) Proline sulfonamide derivatives as orexin receptor antagonists
EP2468732B1 (en) 1H-Quinazoline-2,4-diones
HUP0200602A2 (en) Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use
BR112019018843A2 (en) compound, process for preparing compounds, pharmaceutical composition, combination, process for making a pharmaceutical composition, and method of treating and / or preventing a disorder
CN101341131A (en) Imidazoles as GABA-B receptor modulators
US5236942A (en) 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful in the treatment of Altzheimer's dementia
JP2009521430A (en) GABA-B receptor modulator
MX2013004517A (en) Antagonist for mutated androgen receptor.
US5100906A (en) 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
WO2006062478A1 (en) Novel treatment of gastrointestinal disorders
JP2009521426A (en) Heterocyclic GABA-B modulator
JP2004515449A (en) Small molecule modulator of 6G protein-coupled receptor
CN101341128A (en) Pyrazoles for the treatment of gerd and ibs
EP3958851B1 (en) Allosteric activators of the alpha ia-adrenergic receptor
JP4201252B2 (en) Novel 2,3-benzodiazepine derivative and pharmaceutical composition containing the derivative as an active ingredient
JP6751161B2 (en) Fluorine-containing triazolopyridine compound, method for producing the same, pharmaceutical composition and use
HK40076272A (en) Methods of treating epilepsy using the same
HUE026358T2 (en) Therapeutic agent for cancer pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815789

Country of ref document: EP

Kind code of ref document: A1